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Hyperglycemia is an obvious candidate contributor in the development of 
endothelial dysfunction in association with insulin resistance. A great deal of evidence 
demonstrates that polyphenols and vitamin E can improve endothelial dysfunction, but 
little research has examined whether their metabolites exert protective effects on 
endothelial cells. In the current study, we determined the mechanisms by which 
metabolites can protect against high glucose-induced endothelial dysfunction in human 
aortic endothelial cells (HAECs). Confluent HAECs were treated with 5mM or 25mM 
glucose for 48h, or pretreated with 3-hydroxyphenylpropionic acid (3-HPP) at 1µM, 
Piceatannol (Picea) at 5µM, quercetin 3-glucuronide (Quer-3-glu) at 2µM, and 2,7,8-
trimethyl-2-(beta-carboxyethyl)-6-hydroxychroman (ɤ-CEHC) at 3µM, respectively, for 
24h, and then treated with high glucose (25mM) for 48h. Nitric oxide (NO) production, 
total and phosphorylation of endothelial NO synthase (eNOS), protein kinase B (Akt) and 
extracellular signal regulated kinase (ERK), and reactive oxygen species (ROS)/reactive 
nitrogen species (RNS) production were determined. In HAECs, insulin-stimulated NO 
production (59%), eNOSSer1177, and AktSer473 phosphorylation (1.3-fold and 1.5-fold, 
respectively) was increased (p < 0.05) in cells treated with 5mM glucose. Insulin had no 
stimulatory effect on NO or eNOS signaling in cells treated with 25mM glucose. 
However, cells pretreated for 24h with 3-HPP (1µM), Picea (5µM), Quer-3-glu (2µM), 





normalized (p < 0.05) insulin-stimulated NO production, eNOSSer1177, and AktSer473 
phosphorylation. There was no difference in basal NO production, eNOSSer117, AktSer473, 
ERKThr202/204 phosphorylation, or insulin-stimulated ERKThr202/204 phosphorylation at each 
treatment. ROS/RNS production was stimulated by treatment with 25mM glucose (65%, 
p < 0.05), and prevented when HAECs were pretreated with metabolites. In conclusion, 
metabolites of quercetin, resveratrol, catechin, and gamma tocopherol rescue high 
glucose-induced endothelial dysfunction as evidenced by increased NO production. We 
propose the mechanism occured through a reduction of ROS/RNS that normalized Akt-
mediated eNOSSer1177 phosphorylation.  
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Endothelial dysfunction is a systemic pathological state of the endothelium and 
can be broadly defined as an imbalance between vasodilating mediators (such as NO, 
endothelium-derived hyperpolarizing factor (EDHF) and prostacylin) and 
vasoconstricting mediators (such as endothelin-1, thromboxane A2 and reactive oxygen 
species (ROS)) produced by the endothelial cells (1). It is known that endothelial 
dysfunction is commonly associated with diminished NO bioavailability, which is due to 
impaired NO production by the endothelium and/or increased inactivation of NO by ROS. 
Moreover, current literature indicates that the reduced endothelium-derived NO, 
produced by endothelial nitric-oxide synthase (eNOS), has been identified as a hallmark 
in endothelial dysfunction and the most relevant mechanism in many cardiovascular 
dysfunctions (2). In addition, decreased NO bioavailability is well described in patients 
with type 1 diabetes (3) and type 2 diabetes (4) and also in cardiovascular disorders such 
as hypertension and atherosclerosis associated with insulin resistance (5). 
Diabetic vascular dysfunction is a major clinical problem that predisposes patients 
to a variety of cardiovascular diseases. High glucose (or hyperglycemia) is an important 
causal factor in the development of endothelial dysfunction in diabetes. Many studies 
have indicated that high glucose-induced endothelial dysfunction may be due to increased 
ROS production (6-8). For example, a report has suggested that acute (15–30 min) 





reduced eNOSSer1177 phosphorylation in human umbilical vein endothelial cells 
(HUVECs) (9). The overproduction of ROS can reduce endothelial NO availability via 
different pathways such as formation of peroxynitrite (ONOO-) from NO by superoxide. 
Reduction in NOS enzyme expression and activity can also occur by increasing 
asymmetric dimethylarginine (ADMA) levels, as well as eNOS uncoupling due to 
increased BH4 oxidation to BH2 (7, 10-14).  
Many studies have shown that nutritional supplements, such as grape seed extract, 
resveratrol, quercetin, and vitamin E, can prevent endothelial dysfunction through 
different mechanisms. Recent studies have suggested that grape seed extract has many 
beneficial effects on the cardiovascular system (15), such as reducing inflammatory stress 
(16), preventing high glucose induced impairment of eNOS activity by improving eNOS 
phosphorylation (17), decreasing plasma cholesterol and atherosclerosis (18), lowering 
arterial blood pressure (19), increasing endothelium-dependent relaxation of aortic rings 
(20), as well as improving coronary and aortic flow (21). In addition, the effects of 
resveratrol and quercetin on modulating endothelial function have been widely studied. 
The improvement of endothelial function by these two components was largely attributed 
to enhance endothelial NO bioactivity through multiple mechanisms (22-24), such as 
enhancing eNOS expression (25), phosphorylation of eNOS at Ser1177, AMPK at Thr172 
(26) and BH4 biosynthesis (27), decreasing endogenous eNOS inhibitor (28), scavenging 
superoxide anion (29, 30), inhibiting xanthine oxidase and NADPH oxidase (31), as well 
as increasing intracellular Ca2+ concentration (32). Studies also have demonstrated that 
resveratrol and quercetin can lower blood pressure in hypertensive humans and animals, 





effects are not limited to polyphenols either since many clinical and animal studies have 
showed that gamma tocopherol (ɤ-T), the major form of vitamin E consumed in the US 
diet, has protective effects on the endothelium. Previous work has shown enhanced 
endothelium-dependent hyperemia-induced vasodilatation of brachial artery (37), 
increased NO production and platelet eNOS activity (38), decreased ADP-induced 
platelet aggregation (39), lipid peroxidation, and disruption in NO homeostasis [Mah & 
Bruno, unpublished data, 2012].  
However, the bioavailability of these nutritional supplements is complicated. After 
ingestion, these supplements are quickly digested and absorbed. The dominant forms that 
exist in blood are their physiologic metabolites. Human studies showed that 
supplementation with grape seed polyphenols (1000mg/d) result in increased urinary 
excretion of 3- hydroxyphenylpropionic acid (3-HPP) (0.2µM), suggesting that this 
compound is a major phenolic acid breakdown product in vivo (40). Similarly, ɤ-T 
supplementation (500mg/d) increases plasma ɤ-carboxyethyl– hydroxychroman (ɤ-CEHC) 
(3µM) concentration by > 9-fold [Mah & Bruno, unpublished data, 2012]. Other human 
and animal studies found that piceatannol derived from resveratrol (300 ml of red wine/d) 
is the major metabolite found in liver microsome and blood serum (5µM) (41, 42). In 
addition, a human study demonstrated that quercetin 3-glucuronide (Quer-3-glu) (2µM) 
presents in plasma of human subjects 1.5 h after consumption of onions (100 mg/d-330 
µmol quercetin equivalent) (43). In spite of studies such as the aforementioned ones, 
many previous in vitro studies that have been done to elucidate mechanisms of 
endothelial cell protection have used the parent compounds, not their metabolites. 





of grape seed extract, resveratrol, quercetin, and vitamin E, can protect against high 
glucose-induced endothelial dysfunction. 





Human aortic endothelial cells (HAECs) were purchased commercially (Lonza, 
Carlsbad, California). 3-hydroxyphenylpropionic acid (3-HPP) and quercetin 3-
glucuronide (Quer-3-glu) were purchased from Sigma Chemical (St. Louis, Missouri, 
USA).  Piceatannol (Picea) was purchased from A. G. Scientific Inc. (San Diego, CA, 
USA). ɤ-CEHC was purchased from Encore Pharmaceuticals (Riverside, CA, USA). 
Nitrate/Nitrite colorimetric assay kit was purchased from Cayman Chemical (Ann Arbor, 
MI). OxiSelectTM in vitro ROS/RNS assay kit was purchased from Cell Biolab, Inc. 
(San Diego, CA, USA). Antibodies directed against p-eNOSSer1177, total eNOS, p-
AktSer473, total Akt, p-ERKThr 202/204, total ERK, and actin were purchased from Cell 
Signal Technology (Beverly, MA). All of the other reagents will be purchased from 
Sigma Chemical except special statement.  
 
Cell culture 
HAECs were cultured in T-75 in Medium M199 (GIBCO, CA) containing 2% 
FBS and endothelial growth supplements EGM-2 (Life Technologies, CA) in a 
humidified atmosphere (5% CO2 / 95% O2, 37°C) and passaged when at 80% confluence. 






When HAECs reached 80% confluence, the media in the T75 flask were aspirated 
and removed. 2ml of 0.05% trypsin (Cellgro, Mediatech Inc., Manassaa, Virginia) were 
administered to the cells. The cells were then incubated for 2-3 minutes at 37°C and 
viewed under a microscope to ensure all were dislodged from the flask surface. Proper 
quantity of Medium 199 supplemented with 2% FBS and endothelial growth supplements 
EGM-2 were added to the trypsinized cells and a pipette was used to wash the bottom of 
the flask in order to ensure all cells were dislodged and distributed evenly throughout the 
medium. The cells were then seeded to the appropriate sterile petri dishes for experiments 
and a new T-75 flask for further cell culture. After adding the medium, each container 
was placed in an incubator and cells were grown in a humidified atmosphere of 5% CO2 / 
95% O2 at 37°C.  
 
Cell treatment 
Before the treatment, the cells were incubated overnight in the medium without 
serum. Then, one group of cells was treated with 5mM glucose supplemented with 20mM 
mannitol to maintain osmolarity (vehicle control) for 48h; one group of cells was treated 
with 25mM glucose (positive control) for 48h; the other four groups of cells were pre-
treated with the metabolites (1µM 3-HPP, 5µM Picea, 2µM Quer-3-glu, and 3µM ɤ-
CEHC), respectively, for 24h, and then treated with 25mM glucose for 48h. In the last 10 
minutes, the cells were treated with or without insulin (100nM). Because metabolites 
were dissolved in dimethyl sulfoxide (DMSO, Mallinckrodt, Phillipsburg, New Jersey), 
vehicle control group and positive control group were added the same quantity of DMSO 






HAECs were grown and treated as described earlier. After treatment, the media 
were discarded. The cells were gently washed with iced PBS twice and then collected for 
NO assay. NO was rapidly oxidized to the stable nitrate (NO2
−) and nitrite (NO3
−), and 
NO production was evaluated by measuring the sum concentration of NO2
− and NO3
− 
(NOx) in the cells. Briefly, the collected cells were treated with nitrate reductase to reduce 
nitrate to nitrite, which reacts with the Griess reagent to yield diazochromophore. Each 
sample (80μL), or nitrate standard, containing 10µL nitrate reductase and 10uL nitrate 
reductase cofactors was incubated for 3h at 37 °C. At the end of the incubation period, 
50μL of Griess reagent R1 and 50μL of Griess reagent R2 were added and incubated for 
10 minutes. Total NOx was quantified using the absorbance at 550 nm compared with the 
absorbance of identically prepared nitrite standards. Absorbance data were converted into 
concentrations based on standard curves constructed with sodium nitrate and normalized 
to protein concentration of the samples. 
 
Detection of ROS/RNS 
HAECs were grown and treated as described earlier, but the cells were not treated 
with insulin. After treatment, the media were discarded. The cells were gently washed 
with iced PBS for three times and then collected for ROS/RNS assay. The 
dichlorodihydrofluorescin DiOxyQ (DCFH-DiOxyQ), which is based on similar 
chemistry to the 2', 7’- dichlorodihydrofluorescein diacetate, was used to assess 
ROS/RNS generation. Briefly, the DCFH-DiOxyQ probe was first primed with a quench 





the collected cells were treated with DCFH, ROS/RNS species reacted with DCFH, 
which was rapidly oxidized to highly fluorescent 2', 7’- dichlorodihydrofluorescein 
(DCF). DCF standard was prepared before the measurement. Each sample (50μL) was 
incubated with 50μL catalyst for 5 minutes at 37 °C , and then incubated with 100μL 
DCFH for 15-45 minutes at 37 °C  in dark ambiance. Relative fluorescence was measured 
using a plate reader (Molecular Devices, Silicon Valley, CA) at excitation and emission 
wavelengths of 480 and 530 nm, respectively. Fluorescence data were converted into 




After 48h treatment, HAECs were washed with PBS three times, then lysed using 
cell lysis buffer (in mM, 150 NaCl, 20 Tris-HCl, 2 EDTA, 50 NaF, 10 HEPES, 50 
Na2H2P2O7, and 1% Triton X-100). Protein concentrations of cells were determined by a 
protein assay using bovine serum albumin (BSA) standard (BioRad, Hercules, CA). 
Briefly, the 40g protein loaded in each well was subjected to electrophoresis in 10% 
SDS polyacrylamide gel. Proteins in gels were transferred to PVDF membranes then 
blocked with 5% nonfat milk in TBS-T. After blocking, membranes were incubated 
overnight at 4°C with primary antibodies in 1:1000 dilutions of 5% BSA in Tris buffer 
with 0.05% Tween-20 (phospho specific antibodies) or 5% nonfat milk in TBS-T (non-
phospho specific antibodies). After washing, membranes were incubated for 1h with 
secondary antibodies conjugated to horseradish peroxidase (goat anti-rabbit, Cell Signal 





chemiluminescence (Cell Signal Technology, Beverly, MA). After exposure, membranes 
were stripped and probed for actin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) as a 
loading control. Immunoblot band densities were quantified with a Kodak Gel Logic 
1500 Imaging System and Kodak Molecular Imaging Software (Kodak MI v 4.0, 
Eastman Kodak Company, New Haven, CT). 
 
Cell viability 
Cell viability was assessed in HAECs. The numbers of attached cells were 
accounted in a fixed area before and after different treatments. The 0.25% trypsin was 
served as the positive control. 
 
Statistical analyses 
To prepare Western blot data for statistical analysis, a normalization procedure 
was conducted. 5mM glucose supplemented with 20mM mannitol without insulin 
stimulated (5mM Glu) served as the global control for normalization. For each protein 
assessed by Western blot, all results were normalized to controls of 5mM Glu (phospho : 
total) with those levels set at 1. Fold changes for other treatment conditions were 
calculated and expressed based on controls. Data were analyzed with one-way ANOVA 
using SPSS software and expressed as mean ± SE of four to six independent experiments. 
When main effects were detected, Tukey post hoc tests were conducted to determine 






Dose response experiments 
The concentration of metabolites used in this study was based on previous 
literature (28, 40, 44) [Mah & Bruno, unpublished data, 2012]. A preliminary dose 
response experiment (3-HPP: 0.2, 1, 2µM; Picea: 5, 25, 50µM; Quer-3-glu: 2, 10, 20µM; 
ɤ-CEHC: 3, 15, 30µM, respectively) was conducted to determine the most efficient dose 
for the future study. Interestingly, the most efficient dose of all metabolites was similar to 
their physiological concentration in the blood, such as Picea at 5µM, Quer-3-glu at 2µM, 
and ɤ-CEHC at 3µM. The dose of 3-HPP is 5-fold greater than its physiological 
concentration. 
 
3-HPP, Picea, Quer-3-glu, and ɤ-CEHC restores insulin-stimulated  
NO production inhibited by high glucose in HAECs 
 To study the effects of high glucose, 3-HPP, Picea, Quer-3-glu, and ɤ-CEHC on 
insulin-stimulated NO production in, we examined the ability of insulin to stimulate NO 
synthesis in HAECs (Figure 1).  As shown, insulin (100nM) significantly stimulated NO 
synthesis in HAECs treated with 5mM glucose for 48h (59% increased). In contrast, 
insulin had no significant effect on NO synthesis in HAECs treated with high glucose 
(25mM) for 48h. However, cells pretreated for 24h with 3-HPP (1µM), Picea (5µM), 





glucose (25mM) for 48h, had normalized insulin-stimulated NO synthesis (Figure 1). 
There was no significant difference in basal NO synthesis at each treatment. 
 
3-HPP, Picea, Quer-3-glu, and ɤ-CEHC restores insulin-stimulated  
eNOS and Akt phosphorylation impaired 
 by high glucose in HAECs 
To determine whether insulin-stimulated phosphorylation of eNOS, Akt, and 
ERK was impaired by high glucose and restored by 3-HPP, Picea, Quer-3-glu, and ɤ-
CEHC, respectively, we determined the fold change of ratio of phosphorylated to total 
eNOS, Akt, and ERK in HAECs. Insulin-stimulated phosphorylation of eNOS at Ser1177 
and Akt at Ser473 in HAECs treated with 5mM glucose for 48h (1.3-fold, p < 0.05 and 
1.5-fold, p < 0.05, respectively) (Figure 2, 3). In contrast, insulin had no significant effect 
on phosphorylation of eNOS at Ser1177 and Akt at Ser473 in HAECs treated with high 
glucose (25mM) for 48h (Figure 2, 3). Cells treated with 3-HPP (1µM), Picea (5µM), 
Quer-3-glu (2µM), and ɤ-CEHC (3µM), respectively, before 25mM glucose challenge 
showed a normalization (p < 0.05) of insulin-stimulated phosphorylation of eNOS at 
Ser1177 and Akt at Ser473 to equivalent levels to that of 5mM glucose-incubated controls 
(Figure 2, 3). There was no significant difference in basal eNOSSer117, AktSer473, 
ERKThr202/204 phosphorylation, or insulin-stimulated ERKThr202/204 phosphorylation at each 






3-HPP, Picea, Quer-3-glu, and ɤ-CEHC inhibits high glucose- 
stimulated ROS/RNS production in HAECs 
To determine whether high glucose-stimulated ROS/RNS production and the 
increased production was inhibited by 3-HPP, Picea, Quer-3-glu, and ɤ-CEHC, 
respectively, we assessed the total ROS/RNS production in HAECs (Figure 5). The 
ROS/RNS production was significantly increased in HAECs treated with high glucose 
(25mm) vs. 5mM glucose for 48h (65% increased). 24h pretreatment with 3-HPP (1µM), 
Picea (5µM), Quer-3-glu (2µM), and ɤ-CEHC (3µM), respectively, prevented the rise in 
ROS/RNS evoked by high glucose (25mM) (Figure 5) such that the total ROS/RNS 
production was similar to that of cells in 5mM glucose. 
 
Cell viability is similar between treatments 
We assessed cell viability in HAECs treated with 5mM glucose or high glucose 
(25mM) for 48h, or cells incubated with 25 mM glucose that were pretreated with 3-HPP 
(1µM), Picea (5µM), Quer-3-glu (2µM), and ɤ-CEHC (3µM) for 24h, respectively. There 
was no change of cell viability at each treatment; the cell death level was < 8% and it was 









Figure 1. Effects of 5mM glucose, 25mM glucose, and metabolites, respectively, on 
insulin-stimulated NO production in HAECs. Confluent HAECs were treated with 5mM 
or 25mM glucose for 48h, or pretreated with 3-HPP (1µM), Picea (5µM), Quer-3-glu 
(2µM), and ɤ-CEHC (3µM), respectively, for 24h, and then treated with high glucose 
(25mM) for 48h. Nitrate/nitrite (NOx) production stimulated by insulin (100nM, 10mins) 
was measured using a colorimetric assay kit and normalized to protein content. Results 









Figure 2. Effects of 5mM glucose, 25mM glucose, and metabolites, respectively, on 
insulin-stimulated eNOS phosphorylation (Ser1177) in HAECs. Confluent HAECs were 
treated with 5mM or 25mM glucose for 48h, or pretreated with 3-HPP (1µM), Picea 
(5µM), Quer-3-glu (2µM), and ɤ-CEHC (3µM), respectively, for 24h, and then treated 
with high glucose (25mM) for 48h. Total eNOS and p-eNOSSer1177 protein levels in cell 
extracts were measured by Western blotting. The ratio of phosphorylated to total eNOS 
(mean ± SE) of n = 6 separate experiments are expressed as fold change vs. Glu 5mM (-) 







Figure 3. Effects of 5mM glucose, 25mM glucose, and metabolites, respectively, on 
insulin-stimulated Akt phosphorylation (Ser473) in HAECs. Confluent HAECs were 
treated with 5mM or 25mM glucose for 48h, or pretreated with 3-HPP (1µM), Picea 
(5µM), Quer-3-glu (2µM), and ɤ-CEHC (3µM), respectively, for 24h, and then treated 
with high glucose (25mM) for 48h. Total Akt and p-AktSer473 protein levels in cell 
extracts were measured by Western blotting. The ratio of phosphorylated to total Akt 
(mean ± SE) of n = 4 separate experiments are expressed as fold change vs. Glu 5mM (-) 








Figure 4. Effects of 5mM glucose, 25mM glucose, and metabolites, respectively, on 
insulin-stimulated ERK phosphorylation (Thr202/204) in HAECs. Confluent HAECs 
were treated with 5mM or 25mM glucose for 48h, or pretreated with 3-HPP (1µM), Picea 
(5µM), Quer-3-glu (2µM), and ɤ-CEHC (3µM), respectively, for 24h, and then treated 
with high glucose (25mM) for 48h. Total ERK and p-ERKThr202/204 protein levels in cell 
extracts were measured by Western blotting. The ratio of phosphorylated to total ERK 
(mean ± SE) of n = 4 separate experiments are expressed as fold change vs. Glu 5mM (-) 







Figure 5. Effects of 5mM glucose, 25mM glucose, and metabolites, respectively, on total 
ROS/RNS production. Confluent HAECs were treated with 5mM or 25mM glucose for 
48h, or pretreated with 3-HPP (1µM), Picea (5µM), Quer-3-glu (2µM), and ɤ-CEHC 
(3µM), respectively, for 24h, and then treated with high glucose (25mM) for 48h. DCF 
concentration was measured using a fluorescence assay kit and normalized to protein 
content. Results represent mean ± SE from n = 4 separate experiments. * P < 0.05 vs. Glu 










Figure 6. Cell viability during experiments. Cell viability was assessed in HAECs treated 
with the reagents as shown. Trypsin (.25%) served as the positive control. Results 































Abnormal vascular endothelial function, as defined by measures of NO 
bioavailability, is well described in patients with type 1 and 2 diabetes and in 
cardiovascular disorders that are associated with insulin-resistance, including 
hypertension and atherosclerosis (3-5). Hyperglycemia is an obvious candidate 
contributor in the development of endothelial dysfunction in association with insulin 
resistance. The mechanisms underlying this phenomenon have been widely investigated 
and are likely to be multifactorial (7-10, 14). A great deal of evidence demonstrates that 
grape seed extract, resveratrol, quercetin, and ɤ-T can improve endothelial dysfunction 
and maintain normal cardiovascular function (15, 22-24, 37). However, these substances 
do not predominantly exist in the human plasma. After ingestion, they rapidly 
metabolized to their physiological metabolites, but there is little research that has 
examined whether or not these metabolites exert protective effects on endothelial cell. 
This led us to determine the effects of these metabolites on insulin-stimulated NO 
production impaired by hyperglycemia in HAECs. 
Culture of HAECs in 22.2mM glucose for 5 days was previously reported to 
stimulate basal NO production (45). In contrast, other groups have demonstrated reduced 
basal NO production in response to high glucose in human coronary artery endothelial 
cells and BAECs (46, 47). In the present study, we could not demonstrate any effect of 





with the study of Salt et al. (48) . These differences may be due to the different 
endothelial cell types used or the varied concentration and duration of hyperglycemia 
applied.  
In this study, we have demonstrated that insulin-stimulated NO production was 
increased in HAECs treated with 5mM glucose, but abolished in HAECs treated with 
25mM glucose vs. 5mM glucose. However, this insulin-stimulated NO production was 
restored in HAECs by pretreated with 3-HPP (1µM), Picea (5µM), Quer-3-glu (2µM), 
and ɤ-CEHC (3µM), respectively. To our knowledge, this is the first study to indicate 
these metabolites rescue insulin-stimulated NO production abrogated by high glucose in 
HAECs. 
 In recent years, many studies indicated that multisite phosphorylation of specific 
serine (Ser) or/and threonine (Thr) residues has been involved in regulation of eNOS 
activity, and consequently, NO production (49, 50). We therefore hypothesized that this 
stimulation, inhibition, or restoration of insulin-stimulated NO production was a 
consequence of increased or decreased phosphorylation of kinases downstream of the 
insulin receptor. In this study, we found that insulin-stimulated phosphorylation of eNOS 
at Ser1177 and Akt at Ser473 was increased in HAECs treated with 5mM glucose, abolished 
in HAECs treated with 25mM glucose vs. 5mM glucose, and again, restored by pre-
treated with 3-HPP (1µM), Picea (5µM), Quer-3-glu (2µM), and ɤ-CEHC (3µM), 
respectively. However, there was no difference in basal phosphorylation of eNOSSer117, 
AktSer473, ERKThr202/204, or insulin-stimulated ERKThr202/204 phosphorylation in cells treated 
with 5mM glucose or 25mM glucose.  Basal levels of those proteins were also similar 





eNOS is through Akt-mediated phosphorylation in HAECs. Normally, when insulin 
presents in the blood, it binds to the insulin receptor and phosphorylates the receptor, then 
triggers signaling cascade and mediates the downstream factors. However, insulin-
resistance occurs during hyperglycemia, which desensitizes insulin receptors, and 
therefore, blocks insulin dependent signaling. In our experiments, 25mM glucose resulted 
in insulin-resistance in HAECs. Therefore, insulin-stimulated signaling through 
phosphorylating Ak at Ser473 was interrupted, and subsequently, impaired 
phosphorylation of eNOS at Ser1177. However, 3-HPP, Picea, Quer-3-glu, or ɤ-CEHC 
reversed the negative effect caused by high glucose. 
ROS are attractive candidates as mediators of endothelial dysfunction in diabetic 
rats and in diabetic hypertensive patients (6, 7). Monocytes from patients with diabetes 
showed an increase in production of superoxide relative to those from normal controls (7). 
Increased lipid peroxidation and reduced antioxidant defenses have been demonstrated in 
patients with either type 1 or type 2 diabetes (8). In addition, several in vitro studies 
showed that endothelial cells grown under hyperglycemic concentration of glucose 
(25mM) increases the formation of ROS (51). In the current study, our finding is 
consistent with the previously reports. Further, our data demonstrate that high glucose-
stimulated total ROS/RNS production inhibited by pretreated with 3-HPP (1µM), Picea 
(5µM), Quer-3-glu (2µM), and ɤ-CEHC (3µM), respectively. Although the mechanism 
regulating the decrease in ROS/RNS production by these metabolites was not 
investigated in our study, we speculate it may be due to their antioxidant characteristics. 
It is known that high glucose creates ROS by activation of oxidase enzymes, such as 





to uncoupling when there is increased BH4 oxidation caused by high glucose (7, 10). 
Therefore, ROS production induced by high glucose may have been abolished due to 
antioxidant properties of these metabolites, such as inhibiting oxidase enzyme activities, 
scavenging free radicals, and reducing BH4 oxidation.   
The bioavailability and metabolism of polyphenols are very complicated, and 
need to be clearly resolved in order to better understand their biological role and 
mechanisms of action. After ingestion, polyphenols are rapidly metabolized into 
glucuronated, methylated, or thiol conjugates in the liver, and then circulate in the blood 
stream. These metabolite forms are the dominant forms that are found in the blood. A 
limitation of many previous in vivo studies is that they do not account for the fact that 
these compounds are quickly metabolized prior to and after absorption in the gut. For 
example, quercetin 3-glucuronide (2µM) is present in plasma of human subjects 1.5h 
after consumption of onions (a rich source of quercetin) (43). Given such data, one can 
question the traditional approach of using a parent compounds to investigate and explain 
the mechanism of action in humans. Therefore, a strength of the present study is that we 
have used the metabolite forms, rather than parent compounds to investigate the 
mechanism responsible for improvement of high glucose-induced endothelial dysfunction.  
In summary, we have shown that dominant metabolites of grape seed extract, 
resveratrol, quercetin, and vitamin E, respectively, restore insulin-stimulated NO 
production abolished by high glucose in HAECs, at their physiological concentration or 
5-fold greater. This effect may be due to increasing insulin-stimulated Akt-mediated 
phosphorylation of eNOS at Ser1177. Additionally, at the same concentration, these 





Future studies are required to examine whether there will be some other factors involved 
in this insulin signaling pathway, as well as effects of parent compounds of these 
metabolites side by side on high glucose-induced endothelial dysfunction in HAECs. 
That will help us to further understand the role of these metabolites and find out the 
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